{"title":"一项多机构、随机、双盲、安慰剂对照试验:添加度洛西汀治疗阿片类药物和加巴喷丁类药物难治性癌症相关神经性疼痛:JORTC PAL-08 (DIRECT研究)","authors":"pHiromichi Matsuokap","doi":"10.4172/2165-7386-C1-014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":91127,"journal":{"name":"Journal of palliative care & medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A multi-institutional, randomized, double-blinded, placebo-controlled trial of additive Duloxetine for cancerrelated neuropathic pain refractory to opioids and gabapentinoids: JORTC PAL-08 (DIRECT study)\",\"authors\":\"pHiromichi Matsuokap\",\"doi\":\"10.4172/2165-7386-C1-014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":91127,\"journal\":{\"name\":\"Journal of palliative care & medicine\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of palliative care & medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2165-7386-C1-014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of palliative care & medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7386-C1-014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A multi-institutional, randomized, double-blinded, placebo-controlled trial of additive Duloxetine for cancerrelated neuropathic pain refractory to opioids and gabapentinoids: JORTC PAL-08 (DIRECT study)